Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration

International Journal of Geriatric Psychiatry
C W RitchieD Ames

Abstract

Although the evidence base for the use of antipsychotics in older people with schizophrenia is generally of low quality, it tends to support the use of atypical antipsychotics. Only limited information regarding longer term adherence to these apparently more effective drugs is available. The aim of this study was to determine predictors of adherence to risperidone or olanzapine in patients over 60. Patients receiving care from old age psychiatrists for their schizophrenia were randomised to treatment with olanzapine or risperidone and were followed for up to 3(1/2) years. Kaplan-Meier curves were generated to assess the univariate effect of randomisation drug on long-term adherence and Cox regression adjusted for baseline variables which may have affected adherence. In total, 60.6% of the 66 patients in the study were still taking their randomised drug by the end of the interval in which they remained under observation (64.7% olanzapine and 56.3% risperidone). This difference was non-significant. No baseline variable was associated with an increased risk of non-adherence, though the delivery form of pre-randomisation drug (oral or depot) was weakly (p = 0.054) associated with patients originally on depot being less likely to be...Continue Reading

References

Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Oct 1, 1995·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·D L Streiner
Jan 1, 1997·Schizophrenia Bulletin·W S FentonR K Heinssen
Jun 14, 2003·The Cochrane Database of Systematic Reviews·S ArunpongpaisalP Suchat
Dec 20, 2003·European Journal of Clinical Pharmacology·F PelagottiA Messori
Feb 6, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Hans RittmannsbergerJohannes Wancata
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 24, 2005·Harvard Review of Psychiatry·Dilip V JesteCarl Salzman
Feb 24, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Dan CooperJean-Pierre Grégoire
Feb 27, 2007·International Journal of Geriatric Psychiatry·Martha SajatovicRosalinda V Ignacio
Jun 27, 2007·The Journal of Clinical Psychiatry·Dan CooperJean-Pierre Grégoire

❮ Previous
Next ❯

Citations

Nov 1, 2011·Tropical Doctor·Sangeeta SharmaJahanara Muhyuddin Gajendragad
May 7, 2019·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Taishiro KishimotoChristoph U Correll
Jun 6, 2019·Cadernos de saúde pública·Celline Cardoso Almeida-BrasilMaria das Graças Braga Ceccato
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Adib Essali, Ghassan Ali
Oct 11, 2017·Journal of Psychosocial Nursing and Mental Health Services·Elizabeth CortRobert Howard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

American Journal of Alzheimer's Disease and Other Dementias
Philippe Landreville, Valérie Leblanc
American Journal of Alzheimer's Disease and Other Dementias
Christine L WilliamsKelley Newlin
American Journal of Alzheimer's Disease and Other Dementias
Jeffrey M Jones, Joni L Jones
© 2022 Meta ULC. All rights reserved